MyFinsight
Home
Blog
About
Contact
Download
Download image
Filspari
$11,322K
Kyprolis
$6,740K
Royalty Intangible
Other
$3,761K
Rylaze
$3,221K
Intangible Ohtuvayre
$2,987K
Capvaxive
$1,969K
Vaxneuvance
$1,610K
Teriparatide Injection
$1,321K
QARZIBA
$6,299K
Financial Ohtuvayre
Inventors
$3,047K
Financial Royalty Other
$681K
Intangible Royalty Assets
$32,931K
Financial Royalty Assets
$10,027K
Revenue From Contract
With Customer...
$110K
Royalty
$42,958K
Material Sales Captisol
$8,654K
Contract Revenue And
Other Income
$110K
Net gain
-$13,345K
Income tax benefit
-$10,914K
Total revenues and
income
$51,722K
Gain before income
taxes
-$24,259K
Operating income (gain)
$17,368K
Total operating costs
and expenses
$34,354K
Total non-operating
expenses, net
-$41,627K
Interest income
$6,655K
Gain (loss) from
short-term investments
$3,869K
General and
administrative
$20,836K
Amortization of intangibles
$8,097K
Cost of captisol
$3,273K
Research and development
$2,148K
Gain from change in
fair value of...
-$49,229K
Interest expense
$1,747K
Other non-operating
expense, net
-$1,175K
Back
Back
Income Statement
LIGAND PHARMACEUTICALS INC (LGNDZ)
LIGAND PHARMACEUTICALS INC (LGNDZ)
source: myfinsight.com